Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw

economictimes.indiatimes.com:

“We are very excited with the way we have gained market share in recent times for our biosimilars in the US. We have always been sort of aiming for a 20% market share for our insulins globally and it is happening. I mean, it has happened in the US even sooner than we anticipated largely because of this huge demand. That has kind of created a large opportunity for us in insulins and I think we are benefiting from that, sort of windfall,” says Kiran Mazumdar Shaw, Executive Chairperson, Biocon.

Wanted to begin by asking you about India because I think that is, of course, the biggest talking point at the IGF as well. Clearly it seems like a Goldilocks scenario for India, but the question to you is, is this optimism actually being shared and felt by corporate India as well?

Kiran Mazumdar Shaw: Absolutely, I think India Inc has been optimistic for a long time because I think a lot of geopolitics is basically playing to our favour. And I think apart from that I believe that India provides a very strong case for providing a very robust and resilient supply chain to any strategic partnership in terms of economies of scale, in terms of the tech talent that we provide for supporting these supply chains, etc, etc. So, I think this is a very unique time for India to really take advantage of all that is playing.

Unlock Leadership Excellence with a Range of CXO Courses